Stoke Therapeutics, Inc. 4

Harrison Seth Loring gifted multiple tranches of fully vested Stoke Therapeutics stock options and their underlying common shares from his direct ownership to an irrevocable trust, with no cash consideration.

On July 16, 2026, Harrison Seth Loring reported a series of internal transfers of fully vested stock options in Stoke Therapeutics, Inc., moving in-the-money options (exercise prices ranging from $10.90 to $40.37) and their underlying common shares in matched pairs of dispositions from his direct ownership and corresponding acquisitions by the East Pillar 2026 Irrevocable Trust, a vehicle of which he is a manager and beneficiary. Each line item is coded as a Form 4 transaction type "G" (gift) at a transaction price of $0, reflecting that these were non-cash, no-consideration gifts exempt from short-swing profit rules under Rule 16b-5, rather than open-market purchases or sales. As a result, economic exposure is largely shifted from Mr. Loring’s direct holdings to indirect trust ownership, but the aggregate number of shares tied to his interests remains effectively the same, and no new capital entered or left the issuer.

Filing Facts

CIK

1623526

Ticker

STOK

Form

4

Source Type

fda

Accession

0001404955-26-000006

Alert Tier

5